Device Trial Radar · NCT04591938
FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo CAD: the ENCORE-I Study
Last checked: Nov 20, 2026Latest source record: Oct 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 1, 2019
Primary completion
Jun 1, 2021
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Joost DaemenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Horizon 2020 - European Commission; REVA Medical, Inc.
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, multicentre, non-randomized, investigator-initiated study aiming to assess the safety and efficacy of the Fantom Encore sirolimus-eluting bioresorbable scaffold (BRS).
Conditions
- Percutaneous Coronary Intervention
- Myocardial Revascularization
- Tomography, Optical Coherence
Interventions
Fantom Encore Bioresorbable scaffold implantationDevice
Fantom Encore Bioresorbable scaffold implantation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Device-Oriented Composite Endpoint (DOCE)Time frame: 12 months
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Ziekenhuis Oost-Limburg
Genk, Belgium · Not yet recruiting
Universitair Ziekenhuis Leuven
Leuven, Belgium · Not yet recruiting
Erasmus Medical Center
Rotterdam, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.